Tolerance induction with T cell–dependent protein antigens induces regulatory sialylated IgGs - 31/05/12

Abstract |
Background |
Under inflammatory conditions, T cell–dependent (TD) protein antigens induce proinflammatory T- and B-cell responses. In contrast, tolerance induction by TD antigens without costimulation triggers the development of regulatory T cells. Under both conditions, IgG antibodies are generated, but whether they have different immunoregulatory functions remains elusive.
Objective |
It was shown recently that proinflammatory or anti-inflammatory effector functions of IgG molecules are determined by different Fc N-linked glycosylation patterns. We sought to examine the Fc glycosylation and anti-inflammatory quality of IgG molecules formed on TD tolerance induction.
Methods |
We administered chicken ovalbumin (OVA) with or without costimulus to mice and analyzed OVA-reactive IgG Fc glycosylation. The anti-inflammatory function of differentially glycosylated anti-OVA IgGs was further investigated in studies with dendritic cell cultures and in an in vivo model of allergic airway disease. Additionally, we analyzed the Fc glycosylation pattern of birch pollen–reactive serum IgGs after successful allergen-specific immunotherapy in patients.
Results |
Stimulation with TD antigens under inflammatory conditions induces plasma cells expressing low levels of ⍺2,6-sialyltransferase and producing desialylated IgGs. In contrast, plasma cells induced on tolerance induction did not downregulate ⍺2,6-sialyltransferase expression and secreted immunosuppressive sialylated IgGs that were sufficient to block antigen-specific T- and B-cell responses, dendritic cell maturation, and allergic airway inflammation. Importantly, successful specific immunotherapy in allergic patients also induced sialylated allergen-specific IgGs.
Conclusions |
Our data show a novel antigen-specific immunoregulatory mechanism mediated by anti-inflammatory sialylated IgGs that are formed on TD tolerance induction. These findings might help to develop novel antigen-specific therapies for the treatment of allergy and autoimmunity.
Le texte complet de cet article est disponible en PDF.Key words : Tolerance, IgG antibodies, IgG sialylation, dendritic cells, allergy, asthma, antigen-specific immunotherapy, antigen-specific tolerance, antibody therapy
Abbreviations used : CFA, DC, DTH, IVIG, OVA, PC, SIT, TD, TNP
Plan
| Supported by the German Research Foundation (DFG) to M.E. (EH221-4 and 5), A.P., P.K., and J.K. (SFB/TR22 projects Z1, Z3 and A21). M.E. was a fellow of the Claussen-Simon-Foundation and supported by the Max Planck Institute for Infection Biology, Berlin, Germany. S.E. was supported by the International Max Planck Research School for Infectious Diseases and Immunology, Berlin, Germany. V.B. and M.B. were supported by the German Ministry of Research and Education (03IP511) and the Sonnefeld Foundation. M.C. was supported by grants from the Swedish Research Council (2010-57X-20240) and the Foundations of Wiberg, Österlund, and Hedlund; the Royal Physiographic Society; King Gustaf V’s Memorial Fund; and Hansa Medical AB. |
|
| Disclosure of potential conflict of interest: C. Hess is an employee of Novo Nordisk AIS. M. Huxdorf is an employee of GlaxoSmithKline Research & Development China. Y. Darcan-Nicolaisen is an employee of Richter-Helm Biologics. C. T. Schoen is an employee of UCB Pharma GmbH. M. M. M. Mertes is an employee of Ku Patent. P. König has received research support from Deutsche Forschungsgemeinschaft. M. Collin has consulted for and received research support from Hansa Medical AB and has received research support from the Swedish Research Council, Wiberg’s Foundation, King Gustaf V’s Memorial Fund, Österlund’s Foundation, Hedlund’s Foundation, and the Royal Physiographic Society. M. Ehlers has received research support from the German Research Foundation. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 129 - N° 6
P. 1647 - juin 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
